Amber Lanae Martirosov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Amber Lanae Martirosov has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Melissa Lipari
Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences Wayne State University Detroit Michigan USA
6 shared publications - Candice L. Garwood
Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences Wayne State University Detroit Michigan USA
5 shared publications - Helen D. Berlie
Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences Wayne State University Detroit Michigan USA
5 shared publications - Insaf Mohammad
Department of Pharmacy, Eugene Applebaum College of Pharmacy and Health Sciences Wayne State University Detroit Michigan USA
4 shared publications - Alison Lobkovich
Henry Ford Health System, Detroit, MI
3 shared publications - Christopher Giuliano
Wayne State University
3 shared publications
Latest Publications
- 14 October 2026
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 9 (11) , e70303
A Blueprint for Developing a Concentration in Ambulatory Care Within the PharmD Curriculum
The US healthcare system is grappling with significant challenges, notably a shortage of primary care providers. Ambulatory care pharmacists are increasingly recognized as vital contributors to addressing these challenges. The Accreditation Council for Pharmacy Education Standards 2025 emphasizes preparing Doctor of Pharmacy (PharmD) graduates to be both “practice‐ready” and “team‐ready,” supporting pharmacists' expanding role in addressing primary care shortages as members of interprofessional ambulatory care teams. The evolving healthcare landscape, local community needs, and directives from national pharmacy organizations underscore the importance of developing ambulatory care‐focused curricular concentrations within PharmD programs. In this paper, we describe the development, implementation, and initial evaluation of an ambulatory care concentration (ACC) within a PharmD curriculum and provide a framework adaptable for other pharmacy programs seeking specialized curricular pathways. The purpose of the ACC was to prepare graduates for entry‐level ambulatory care practice and postgraduate training. Graduates of the inaugural ACC cohort reported high overall satisfaction with the concentration and enhanced preparedness for ambulatory care practice. Early career outcomes include three graduates currently completing ambulatory care residencies. The seven graduates in practice are in ambulatory care, specialty pharmacy, managed care, clinical community pharmacy, community pharmacy ( n = 2), and inpatient clinical practice (post‐residency). The ACC was implemented within the PharmD curriculum and was well received by students. Early findings support the purpose of the ACC to prepare graduates for ambulatory care practice and postgraduate training. This model provides an approach that pharmacy programs may adapt to develop practice‐focused curricular pathways by leveraging existing institutional resources.
- 14 October 2026
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 9 (11) , e70303
A Blueprint for Developing a Concentration in Ambulatory Care Within the PharmD Curriculum
The US healthcare system is grappling with significant challenges, notably a shortage of primary care providers. Ambulatory care pharmacists are increasingly recognized as vital contributors to addressing these challenges. The Accreditation Council for Pharmacy Education Standards 2025 emphasizes preparing Doctor of Pharmacy (PharmD) graduates to be both “practice‐ready” and “team‐ready,” supporting pharmacists' expanding role in addressing primary care shortages as members of interprofessional ambulatory care teams. The evolving healthcare landscape, local community needs, and directives from national pharmacy organizations underscore the importance of developing ambulatory care‐focused curricular concentrations within PharmD programs. In this paper, we describe the development, implementation, and initial evaluation of an ambulatory care concentration (ACC) within a PharmD curriculum and provide a framework adaptable for other pharmacy programs seeking specialized curricular pathways. The purpose of the ACC was to prepare graduates for entry‐level ambulatory care practice and postgraduate training. Graduates of the inaugural ACC cohort reported high overall satisfaction with the concentration and enhanced preparedness for ambulatory care practice. Early career outcomes include three graduates currently completing ambulatory care residencies. The seven graduates in practice are in ambulatory care, specialty pharmacy, managed care, clinical community pharmacy, community pharmacy ( n = 2), and inpatient clinical practice (post‐residency). The ACC was implemented within the PharmD curriculum and was well received by students. Early findings support the purpose of the ACC to prepare graduates for ambulatory care practice and postgraduate training. This model provides an approach that pharmacy programs may adapt to develop practice‐focused curricular pathways by leveraging existing institutional resources.
- 18 February 2026
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 46 (3) , e70121
Aspirin Deprescribing Interventions for Primary Prevention: A Systematic Review and Proposed Guidance for Deprescribing
Recent literature indicates that the benefits of aspirin use for primary prevention of atherosclerotic cardiovascular disease (ASCVD) may be equivocal to the risk. This has resulted in several organizations making updates to their clinical practice guidance on appropriate use. Despite this narrower scope, specific guidance on how to deprescribe aspirin in patients already on therapy for primary prevention is lacking. The purpose of this paper is two‐fold: to provide a systematic review of the literature on aspirin deprescribing strategies and propose a practical aspirin deprescribing algorithm when used discordantly with current recommendations for primary prevention. We conducted searches in databases including EMBASE, PubMed, Web of Science, Scopus, and CINAHL from January 2018 to March 2025. One hundred and sixty‐seven studies were screened, and 13 articles were included. The studies utilized a variety of interventions to impact aspirin deprescribing. In each of the studies included, there was at least some type of prompt to trigger deprescribing aspirin. However, a consistent approach was not defined. A multidisciplinary model occurred in half of the studies included, which resulted in the highest reported deprescribing rate of 78%. However, there were limited descriptions of patient‐related outcomes as a result of deprescribing, warranting additional studies. A deprescribing algorithm can assist in guiding aspirin deprescribing for primary prevention of ASCVD while considering patient preferences in an individually tailored approach.
- 18 February 2026
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 46 (3) , e70121
Aspirin Deprescribing Interventions for Primary Prevention: A Systematic Review and Proposed Guidance for Deprescribing
Recent literature indicates that the benefits of aspirin use for primary prevention of atherosclerotic cardiovascular disease (ASCVD) may be equivocal to the risk. This has resulted in several organizations making updates to their clinical practice guidance on appropriate use. Despite this narrower scope, specific guidance on how to deprescribe aspirin in patients already on therapy for primary prevention is lacking. The purpose of this paper is two‐fold: to provide a systematic review of the literature on aspirin deprescribing strategies and propose a practical aspirin deprescribing algorithm when used discordantly with current recommendations for primary prevention. We conducted searches in databases including EMBASE, PubMed, Web of Science, Scopus, and CINAHL from January 2018 to March 2025. One hundred and sixty‐seven studies were screened, and 13 articles were included. The studies utilized a variety of interventions to impact aspirin deprescribing. In each of the studies included, there was at least some type of prompt to trigger deprescribing aspirin. However, a consistent approach was not defined. A multidisciplinary model occurred in half of the studies included, which resulted in the highest reported deprescribing rate of 78%. However, there were limited descriptions of patient‐related outcomes as a result of deprescribing, warranting additional studies. A deprescribing algorithm can assist in guiding aspirin deprescribing for primary prevention of ASCVD while considering patient preferences in an individually tailored approach.
- 2 September 2025
- Published by Elsevier in Clinics in Geriatric Medicine
- Vol. 41 (4) , 597-612
Enhancing Pulmonary Care in Older Adults
- 2 September 2025
- Published by Elsevier in Clinics in Geriatric Medicine
- Vol. 41 (4) , 597-612
Enhancing Pulmonary Care in Older Adults
- 27 July 2025
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 8 (10) , 1027-1045
Navigating the Alphabet Soup of Interstitial Lung Diseases (ILD): The Role of Pharmacists
Interstitial lung disease (ILD) is a group of heterogeneous disorders that carries a poor prognosis and is characterized by lung parenchyma inflammation and/or fibrosis. It is further categorized into specific subtypes of ILD, which drive treatment approaches. Diagnosis is elusive with non‐specific respiratory symptoms, and dyspnea is the most common symptom experienced by patients. A multidisciplinary approach is recommended to collaboratively diagnose ILD and direct treatment. Historically, treatment of most ILDs has focused on the use of immunosuppressive agents and targeted pharmacotherapies for select ILD subtypes, increasing over the past decade. In select subtypes of ILD, antifibrotics have slowed the progression of loss of lung function, especially forced vital capacity. Adverse events can be significant and lead to the discontinuation of disease‐modifying therapies. These agents can be used as monotherapy or combined in select scenarios, highlighting the importance of evaluating the risk–benefit profile. Pharmacist involvement in the care of this population has been shown to improve access to medications and prevent the discontinuation of evidence‐based therapeutics due to adverse event mitigation approaches. This review summarizes the current understanding and management of ILDs and highlights the pharmacist role in disease state optimization.
- 27 July 2025
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 8 (10) , 1027-1045
Navigating the Alphabet Soup of Interstitial Lung Diseases (ILD): The Role of Pharmacists
Interstitial lung disease (ILD) is a group of heterogeneous disorders that carries a poor prognosis and is characterized by lung parenchyma inflammation and/or fibrosis. It is further categorized into specific subtypes of ILD, which drive treatment approaches. Diagnosis is elusive with non‐specific respiratory symptoms, and dyspnea is the most common symptom experienced by patients. A multidisciplinary approach is recommended to collaboratively diagnose ILD and direct treatment. Historically, treatment of most ILDs has focused on the use of immunosuppressive agents and targeted pharmacotherapies for select ILD subtypes, increasing over the past decade. In select subtypes of ILD, antifibrotics have slowed the progression of loss of lung function, especially forced vital capacity. Adverse events can be significant and lead to the discontinuation of disease‐modifying therapies. These agents can be used as monotherapy or combined in select scenarios, highlighting the importance of evaluating the risk–benefit profile. Pharmacist involvement in the care of this population has been shown to improve access to medications and prevent the discontinuation of evidence‐based therapeutics due to adverse event mitigation approaches. This review summarizes the current understanding and management of ILDs and highlights the pharmacist role in disease state optimization.
- 23 May 2025
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 17 (9) , 102384
Choose your own adventure: Perception of gamification in continuing pharmacy education
- 23 May 2025
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 17 (9) , 102384
Choose your own adventure: Perception of gamification in continuing pharmacy education
- 4 April 2024
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 64 (4) , 102086
The struggle is real: Facilitating pharmacy student success on rotations when challenges arise
- 4 April 2024
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 64 (4) , 102086
The struggle is real: Facilitating pharmacy student success on rotations when challenges arise
- 3 January 2024
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 16 (3) , 184-195
Evaluation of an ambulatory care elective to improve practice readiness perceptions utilizing entry-level competencies
- 3 January 2024
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 16 (3) , 184-195
Evaluation of an ambulatory care elective to improve practice readiness perceptions utilizing entry-level competencies
- 14 December 2023
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 58 (9) , 956-971
Systemic-Sclerosis-Related Interstitial Lung Disease: A Review of the Literature and Recommended Approach for Clinical Pharmacists
Objective: To describe the efficacy, safety, and clinical utility of pharmacologic agents in the treatment of systemic sclerosis-related interstitial lung disease (SSc-ILD). Data Sources: A review of the literature was performed using the terms lung diseases, (interstitial/therapy) AND (scleroderma, systemic/therapy) OR (scleroderma, systemic) AND (lung diseases, interstitial/therapy) in PubMed, Ovid MEDLINE, CINAHL, and Web of Science. ClinicalTrials.gov was also searched to identify ongoing studies. The initial search was performed in October 2022, with follow-up searches performed in October 2023. Study Selection and Data Abstraction: Articles reviewed were limited to those written in the English language, human studies, and adult populations. Data Synthesis: A variety of therapeutic agents, including mycophenolate, azathioprine, cyclophosphamide (CYC), rituximab (RTX), nintedanib, and tocilizumab (TCZ) have slowed the rate of decline in forced vital capacity (FVC) and disease progression. Only nintedanib and TCZ have a labeled indication for SSc-ILD. Two agents, belimumab and pirfenidone, have shown encouraging results in smaller phase II and phase III studies, but have yet to be approved by the Food and Drug Administration. Relevance to Patient Care and Clinical Practice: Patients with pulmonary manifestations of SSc-ILD have worse outcomes and lower survival rates compared with those without. It is imperative that disease management be individualized to achieve optimal patient-centered care. Pharmacists are uniquely suited to support this individualized management. Conclusion: Numerous pharmacologic agents have been studied and repurposed in the treatment of SSc-ILD, with nintedanib and TCZ gaining approval to slow the rate of decline in pulmonary function in SSc-ILD. Other agents, including belimumab and pirfenidone, are on the horizon as potential treatment options; but further studies are needed to compare their efficacy and safety with the current standard of care.
- 14 December 2023
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 58 (9) , 956-971
Systemic-Sclerosis-Related Interstitial Lung Disease: A Review of the Literature and Recommended Approach for Clinical Pharmacists
Objective: To describe the efficacy, safety, and clinical utility of pharmacologic agents in the treatment of systemic sclerosis-related interstitial lung disease (SSc-ILD). Data Sources: A review of the literature was performed using the terms lung diseases, (interstitial/therapy) AND (scleroderma, systemic/therapy) OR (scleroderma, systemic) AND (lung diseases, interstitial/therapy) in PubMed, Ovid MEDLINE, CINAHL, and Web of Science. ClinicalTrials.gov was also searched to identify ongoing studies. The initial search was performed in October 2022, with follow-up searches performed in October 2023. Study Selection and Data Abstraction: Articles reviewed were limited to those written in the English language, human studies, and adult populations. Data Synthesis: A variety of therapeutic agents, including mycophenolate, azathioprine, cyclophosphamide (CYC), rituximab (RTX), nintedanib, and tocilizumab (TCZ) have slowed the rate of decline in forced vital capacity (FVC) and disease progression. Only nintedanib and TCZ have a labeled indication for SSc-ILD. Two agents, belimumab and pirfenidone, have shown encouraging results in smaller phase II and phase III studies, but have yet to be approved by the Food and Drug Administration. Relevance to Patient Care and Clinical Practice: Patients with pulmonary manifestations of SSc-ILD have worse outcomes and lower survival rates compared with those without. It is imperative that disease management be individualized to achieve optimal patient-centered care. Pharmacists are uniquely suited to support this individualized management. Conclusion: Numerous pharmacologic agents have been studied and repurposed in the treatment of SSc-ILD, with nintedanib and TCZ gaining approval to slow the rate of decline in pulmonary function in SSc-ILD. Other agents, including belimumab and pirfenidone, are on the horizon as potential treatment options; but further studies are needed to compare their efficacy and safety with the current standard of care.
- 28 October 2023
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 58 (8) , 827-833
Zavegepant Intranasal Spray for Migraines
Objective: The objective is to review the pharmacology, efficacy, and safety of intranasal zavegepant in the acute treatment of migraine with or without aura. Data source: PubMed, Embase database, and ClinicalTrials.gov were searched using the following terms: Zavzpret, Zavegepant, BHV-3500, and migraine. Study selection and data extraction: Articles published in English from January 2013 to September 2023 related to pharmacology, safety, efficacy, and clinical trials were assessed. Data synthesis: In a phase 2/3 trial, zavegepant 10 and 20 mg were more effective than placebo on primary endpoints of freedom of pain (22.5%, 23.1%, and 15.5%, respectively), and freedom from most bothersome symptoms (MBSs) (41.9%, 47.9%, and 33.7%, respectively) 2 hours after treatment. The incidence of adverse effects for both doses was similar to placebo. In a phase 3 trial, zavegepant 10 mg was compared with placebo. Two hours after treatment, more patients in the zavegepant group achieved pain freedom (24% vs 15%) and relief from MBSs (40% vs 31%) compared with placebo. Common adverse events included dysgeusia (21% zavegepant vs 5% placebo) and nasal discomfort (5% zavegepant vs 1% placebo). Relevance to patient care and clinical practice in comparison with existing drugs: Zavegepant is indicated for acute treatment of migraine with or without aura in adults. Zavegepant method of administration and prompt relief of migraine symptoms may be an attractive alternative to triptans for those in need of relief. Conclusion: Zavegepant may be a convenient and useful acute treatment option for migraines with and without aura.
- 28 October 2023
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 58 (8) , 827-833
Zavegepant Intranasal Spray for Migraines
Objective: The objective is to review the pharmacology, efficacy, and safety of intranasal zavegepant in the acute treatment of migraine with or without aura. Data source: PubMed, Embase database, and ClinicalTrials.gov were searched using the following terms: Zavzpret, Zavegepant, BHV-3500, and migraine. Study selection and data extraction: Articles published in English from January 2013 to September 2023 related to pharmacology, safety, efficacy, and clinical trials were assessed. Data synthesis: In a phase 2/3 trial, zavegepant 10 and 20 mg were more effective than placebo on primary endpoints of freedom of pain (22.5%, 23.1%, and 15.5%, respectively), and freedom from most bothersome symptoms (MBSs) (41.9%, 47.9%, and 33.7%, respectively) 2 hours after treatment. The incidence of adverse effects for both doses was similar to placebo. In a phase 3 trial, zavegepant 10 mg was compared with placebo. Two hours after treatment, more patients in the zavegepant group achieved pain freedom (24% vs 15%) and relief from MBSs (40% vs 31%) compared with placebo. Common adverse events included dysgeusia (21% zavegepant vs 5% placebo) and nasal discomfort (5% zavegepant vs 1% placebo). Relevance to patient care and clinical practice in comparison with existing drugs: Zavegepant is indicated for acute treatment of migraine with or without aura in adults. Zavegepant method of administration and prompt relief of migraine symptoms may be an attractive alternative to triptans for those in need of relief. Conclusion: Zavegepant may be a convenient and useful acute treatment option for migraines with and without aura.
- 24 June 2023
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 15 (6) , 587-592
Podcasts and videos and slides…oh my!: Traditional vs. nontraditional teaching methods in remote settings
- 24 June 2023
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 15 (6) , 587-592
Podcasts and videos and slides…oh my!: Traditional vs. nontraditional teaching methods in remote settings